elecoglipron (AZD5004) / Eccogene, AstraZeneca - LARVOL DELTA

Elecoglipron Reduces Central Adiposity in Adults With High WtHR: Post Hoc Analysis From VISTA (OBESITY WEEK 2026) - No abstract available

Clinical • Retrospective data • Obesity

Elecoglipron Improves Beta-Cell Function and Insulin Resistance in Adults With Type 2 Diabetes (OBESITY WEEK 2026) - No abstract available

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Elevate-HF: A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF (clinicaltrials.gov) - P3 | N=6950 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure

Elevate-CKD: A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. (clinicaltrials.gov) - P3 | N=7000 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Kidney Disease • Nephrology • Renal Disease

Regression from prediabetes to normoglycaemia following treatment with elecoglipron, an oral GLP-1 receptor agonist (EASD 2026) - P2 | "In adults living with obesity or overweight, prediabetes is associated with an adverse cardiometabolic profile. Elecoglipron produced clinically meaningful reductions in body weight and central adiposity and improved glycaemic control, with high rates of regression to normoglycaemia among those with prediabetes. These findings support further evaluation of elecoglipron for prediabetes management in populations at risk."

Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Treatment with elecoglipron, an oral, once-daily, small molecule GLP-1RA, improves non-invasive biomarkers of liver function in the 26-week phase 2b SOLSTICE trial: post-hoc analysis (EASD 2026) - P2 | "This post-hoc analysis evaluated the effect of elecoglipron vs. placebo and oral semaglutide (oSema) on serum-based noninvasive liver biomarkers over 26 weeks. Materials and In the SOLSTICE study, a 26-week, Phase 2b global trial, 406 adults with T2D managed on diet/exercise alone or monotherapy (metformin or SGLT2i) were randomized to once-daily elecoglipron (5, 15, or 25 mg without dose-escalation or three titration regimens targeting 50 and 75 mg), matching placebo, or open-label oSema titrated to 14 mg... Over 26 weeks, elecoglipron demonstrated greater reductions in non-invasive biomarkers of liver function than placebo. These findings support a favourable metabolic profile of elecoglipron, warranting further evaluation in longer-term studies."

Biomarker • Non-invasive • P2b data • Retrospective data • Diabetes • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (clinicaltrials.gov) - P3 | N=351 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Eluminate-3: A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin (clinicaltrials.gov) - P3 | N=600 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Elevate-CKD: A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. (clinicaltrials.gov) - P3 | N=7000 | Not yet recruiting | Sponsor: AstraZeneca

New P3 trial • Chronic Kidney Disease • Nephrology • Renal Disease

A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (clinicaltrials.gov) - P3 | N=351 | Not yet recruiting | Sponsor: AstraZeneca

New P3 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants (clinicaltrials.gov) - P1 | N=152 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open

Elevate-HF: A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF (clinicaltrials.gov) - P3 | N=6950 | Not yet recruiting | Sponsor: AstraZeneca

New P3 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

AZD5004: Data from P1 trial (NCT07444424) in healthy volunteers in H2 2026 (AstraZeneca) - H1 and Q2 2026 Results

P1 data • Obesity

AZD5004: Data from P3 Embold trial (NCT07667803) for obesity/overweight with T2D post 2027 (AstraZeneca) - H1 and Q2 2026 Results: Data from P1 trial (NCT07455825) in healthy volunteers in H2 2026

P1 data • P3 data • Obesity

A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants (clinicaltrials.gov) - P1 | N=152 | Not yet recruiting | Sponsor: AstraZeneca

New P1 trial

A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed

Trial completion

Eluminate-4: A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (clinicaltrials.gov) - P3 | N=900 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Eluminate-5: A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P3 | N=2000 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Eluminate-1: A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P3 | N=800 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Eluminate-2: A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus (clinicaltrials.gov) - P3 | N=1200 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Embold: A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM (clinicaltrials.gov) - P3 | N=4500 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Elecoglipron: "Daily oral elecoglipron demonstrated clinically meaningful weight reductions in adults living with obesity or overweight without T2D"; Obesity (AstraZeneca) - ADA 2026: "No indication of a plateau in weight loss was observed by 36 weeks; Safety and tolerability profile was consistent with the GLP-1 RA class with no unexpected safety signals"

P2b data • Obesity

A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants (clinicaltrials.gov) - P1 | N=48 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed

Embold: A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM (clinicaltrials.gov) - P3 | N=4500 | Not yet recruiting | Sponsor: AstraZeneca

New P3 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Eluminate-4: A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (clinicaltrials.gov) - P3 | N=900 | Not yet recruiting | Sponsor: AstraZeneca

New P3 trial • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus